We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Dec 2020
  • Code : CMI4350
  • Pages :105
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Advanced glycation end products (AGEs) are a group of compounds, which are formed by non-enzymatic reactions between carbonyl groups of reducing sugars and free amino groups of proteins, lipids or nucleic acids and can be obtained exogenously from diet or formed endogenously within the body. AGEs accumulate intracellularly and extracellularly in all tissues and body fluids and can cross-link with other proteins and thus affect their normal functions.

The global advanced glycation end products market is estimated to be valued at US$ 1,368.5 million in 2020 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020-2027).

Figure 1. Global Advanced Glycation End Products Market Share (%), By Region, 2019

ADVANCED GLYCATION END PRODUCTS MARKET

To learn more about this report, request a free sample copy

Increasing cases of cancer is expected to propel the market growth over the forecast period

The increasing number of cancer cases worldwide is expected to boost the market growth, as AGEs significantly increase the level of inflammation in the body which has long been associated with the development of cancer. For instance, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024 in the U.S.

Similarly, according to the American Cancer Society, 2015, an estimated 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer death.

Advanced Glycation End Products Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,368.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.3% 2027 Value Projection: US$ 2,130.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Non-fluorescent AGEs, Fluorescent AGEs.
  • By Application: Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, Others.
  • By End User: Hospitals, Specialty Clinics, Homecare Settings.
Companies covered:

Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, and Rodan & Fields, LLC

Growth Drivers:
  • Increasing product approvals and launches
  • Increasing number of aesthetic procedures
  • Increasing collaborations, acquisitions, and partnerships
Restraints & Challenges:
  • High cost of aesthetic procedures

 Figure 2. Global Advanced Glycation End Products Market Share (%), by Type, 2020

ADVANCED GLYCATION END PRODUCTS MARKET

To learn more about this report, request a free sample copy

Increasing cases of neurodegenerative diseases is expected to drive the market growth over the forecast period

Increasing cases of neurodegenerative diseases such as Alzheimer’s, Parkinson’s diseases, and other are expected to drive the market growth over the forecast period, as AGEs are proteins and glycated after exposure to sugars that is contribute to the development of neurodegenerative diseases.  For instance, according to the World Alzheimer Report 2015 published by Alzheimer’s Disease International (ADI), in 2015 the new dementia cases in the regions were 4.9 million (49.0%) in Asia, 2.5 million (25.0%) in Europe, 1.7 million (18.0%) in the Americas, and 0.8 million (8.0%) in Africa. Furthermore, according to the Parkinson's UK, in 2015 there were around 137,000 people suffered from Parkinson’s in the U.K.

Global Advanced Glycation End Products Market – Impact of Coronavirus (Covid-19) Pandemic

Advanced glycation products (AGEs) resulting from the fixing of sugars on proteins, create cross links which definitively reduce the elasticity of elastin used in the aesthetic procedures. The American Society of Plastic Surgeons has recommended to postpone all the elective or non-essential services due to which the number of aesthetic procedures such as chemical peel, botulinum toxin therapy, dermabrasion, and others have decreased hindering the advanced glycation end products market growth. According to the article published in the Aesthetic Journal on April 03, 2020, around 81% of clinics are closed and 67% are experiencing reduction in revenue due to the COVID-19 lockdown in London.

Furthermore, several skincare and cosmetic companies are observing a decline in sales due to the COVID-19 pandemic. For instance, on May 12, 2020, Shiseido Company, a Japan-based multinational personal care company, released its financial statement for the first quarter of 2020 reporting a 14.6% and 19.2% year-on-year net sales decline in the American and Asia Pacific business, respectively.

Advanced Glycation End Products Market Restraint

High cost of aesthetic procedures is expected to hinder the market growth over the forecast period. According to the American Society of Plastic Surgeons, the average cost of botox treatment is US$ 397 in the U.S. while a single session of microdermabrasion costs around US$ 131 and the cost of chemical peel is around US$ 669.

Key Players

Major players operating in the global advanced glycation end products market include Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, Rodan & Fields, LLC, and others.

Frequently Asked Questions

The global advanced glycation end products market size is estimated to be valued at US$ 21.06 billion in 2019 and is expected to exhibit a CAGR of 7.3% between 2020 and 2027.

The increasing launches of advanced glycation end products, increasing number of chronic diseases, research and development in advanced glycation end products by major players, and increasing geriatric population are driving the Advanced Glycation End Products market growth.

Non-fluorescent AGEs segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.

North America advanced glycation end products market is expected to generate highest revenue share during the forecast period.

Major factors hampering growth of the market include high cost of cosmetic procedures.

Major players operating in the global advanced glycation end products market include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others. .

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo